News

Recent news about Panacea Venture and select portfolio companies

May 13, 2025

Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans

The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.

May 13, 2025

Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans

The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.

October 1, 2024

Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.

October 1, 2024

Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.

September 9, 2024

TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer

September 9, 2024

TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer

June 26, 2024

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

June 26, 2024

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

June 25, 2024

Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies

Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]

June 25, 2024

Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies

Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]